OTCM
TMLCF
Market cap14mUSD
Oct 19, Last price
0.03USD
1D
-5.33%
IPO
-33.95%
Name
Mountain Valley MD Holdings Inc
Chart & performance
P/E
—
P/S
255.56
EPS
—
Div yield, %
—
Shs. 5Y
5.98%
Rev. 5Y
%
Revenues
65k
+32.65%
Net income
-3m
L-62.59%
CFO
-2m
L-46.00%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Mountain Valley MD Holdings Inc., operating through its subsidiary Mountain Valley MD Inc., functions as a health and wellness enterprise. The company focuses on deploying and licensing its proprietary innovations to external entities within the pharmaceutical, vaccine, and nutritional supplement sectors. Its portfolio encompasses Quicksome, an advanced technology for oral drug formulation and delivery; Quicksol, designed for enhancing solubility; and a dose-sparing adjuvant. Additionally, the firm is actively developing IM032, a compound currently being evaluated in male beagle dogs to assess intramuscular versus subcutaneous administration methods. Mountain Valley MD Holdings Inc. is headquartered in Concord, Canada.
Key people
Chief Financial Officer, Corporate Secretary · since 2024
David Batchelor
Director · since 2025
Dennis Hancock
Chairman of the Board, President, Chief Executive Officer · since 2020
Paul Lockhard
Independent Director · since 2020
Headquarters & legal address
475 West Georgia Street
Suite 610
Vancouver, BC V6B 4M9
CA
Suite 610
Vancouver, BC V6B 4M9
CA
Previous name
Meadow Bay Capital Corporation
Previous name
MEADOW BAY GOLD CORPORATION
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||